多发性骨髓瘤全基因组体细胞改变揭示一个预后优越的亚组
该研究对183例新诊断多发性骨髓瘤患者进行深度全基因组测序,患者接受来那度胺、硼替佐米和地塞米松(RVD)方案或RVD联合自体干细胞移植(ASCT)治疗。研究发现一个基因组定义的亚组(占新诊断患者17%),其特征为低DNA损伤(低基因组瘢痕评分伴9号染色体获得),预后优越(69个月总生存率100%),并在大型独立队列中验证。该亚组的总生存独立于国际分期系统(ISS)和微小残留病(MRD)状态。
要点
- 深度全基因组测序识别出17%的新诊断骨髓瘤患者具有低DNA损伤和9号染色体获得,预后优越。
- 该亚组69个月总生存率为100%,并在独立队列中验证。
- 该亚组总生存独立于ISS和MRD状态,可区分高危和低危超二倍体骨髓瘤。
核心结论
- 该研究识别出一个具有延长生存期的良好预后基因组亚组,将影响未来治疗算法和研究规划。
研究设计与样本
- 对183例新诊断多发性骨髓瘤患者进行深度全基因组测序,患者接受RVD或RVD+ASCT治疗,整合基因组标志与临床数据。
主要发现
- 多发性骨髓瘤亚组间突变负荷和突变过程存在显著差异。
- 几乎所有亚组均激活DNA修复相关特征作为晚期突变过程,而APOBEC特征(靶向C>G)在高危骨髓瘤的中间进展期激活。
- 识别出一个基因组定义的亚组(占新诊断患者17%),具有低DNA损伤(低基因组瘢痕评分伴9号染色体获得)和优越预后(69个月总生存率100%),并在大型独立队列中验证。
- 该亚组可区分低危和高危超二倍体骨髓瘤,并识别无进展生存延长的患者。
- 该亚组基因组特征包括较低突变负荷、年龄相关突变显著贡献以及频繁NRAS突变,其总生存独立于ISS和MRD状态。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiple myeloma (MM) is accompanied by heterogeneous somatic alterations. The overall goal of this study was to describe the genomic landscape of myeloma using deep whole-genome sequencing (WGS) and develop a model that identifies patients with long survival. METHODS: We analyzed deep WGS data from 183 newly diagnosed patients with MM treated with lenalidomide, bortezomib, and dexamethasone (RVD) alone or RVD + autologous stem cell transplant (ASCT) in the IFM/DFCI 2009 study (ClinicalTrials.gov identifier: NCT01191060). We integrated genomic markers with clinical data. RESULTS: We report significant variability in mutational load and processes within MM subgroups. The timeline of observed activation of mutational processes provides the basis for 2 distinct models of acquisition of mutational changes detected at the time of diagnosis of myeloma. Virtually all MM subgroups have activated DNA repair-associated signature as a prominent late mutational process, whereas APOBEC signature targeting C>G is activated in the intermediate phase of disease progression in high-risk MM. Importantly, we identify a genomically defined MM subgroup (17% of newly diagnosed patients) with low DNA damage (low genomic scar score with chromosome 9 gain) and a superior outcome (100% overall survival at 69 months), which was validated in a large independent cohort. This subgroup allowed us to distinguish patients with low- and high-risk hyperdiploid MM and identify patients with prolongation of progression-free survival. Genomic characteristics of this subgroup included lower mutational load with significant contribution from age-related mutations as well as frequent NRAS mutation. Surprisingly, their overall survival was independent of International Staging System and minimal residual disease status. CONCLUSION: This is a comprehensive study identifying genomic markers of a good-risk group with prolonged survival. Identification of this patient subgroup will affect future therapeutic algorithms and research planning.
引用
- Samur MK, Aktas Samur A, Fulciniti M, et al. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020. PMID: 32687451. doi:10.1200/JCO.20.00461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。